Delayed haemolytic transfusion reaction in paediatric patients with sickle cell disease: A retrospective study in a French national reference centre.
Marica RossiFrançoise PirenneEnora Le RouxDjamel SmaïneMarie BelloyStéphanie Eyssette-GuerreauNathalie CouqueLaurent HolvoetGhislaine IthierValentine BrousseBérengère KoehlAlbert FayeMalika BenkerrouFlorence MissudPublished in: British journal of haematology (2022)
Delayed haemolytic transfusion reaction (DHTR) is a life-threatening haemolytic anaemia following red blood cell transfusion in patients with sickle cell disease, with only scarce data in children. We retrospectively analysed 41 cases of DHTR in children treated between 2006 and 2020 in a French university hospital. DHTR manifested at a median age of 10.5 years, symptoms occurred a median of 8 days after transfusion performed for an acute event (63%), before surgery (20%) or in a chronic transfusion programme (17%). In all, 93% of patients had painful crisis. Profound anaemia (median 49 g/L), low reticulocyte count (median 140 ×10 9 /L) and increased lactate dehydrogenase (median 2239 IU/L) were observed. Antibody screening was positive in 51% of patients, and more frequent when there was a history of alloimmunisation. Although no deaths were reported, significant complications occurred in 51% of patients: acute chest syndrome (12 patients), cholestasis (five patients), stroke (two patients) and kidney failure (two patients). A further transfusion was required in 23 patients and corticosteroids were used in 21 to reduce the risk of additional haemolysis. In all, 13 patients subsequently received further transfusions with recurrence of DHTR in only two. The study affords a better overview of DHTR and highlights the need to establish guidelines for its management in children.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- prognostic factors
- intensive care unit
- coronary artery disease
- emergency department
- randomized controlled trial
- physical activity
- public health
- patient reported outcomes
- machine learning
- liver failure
- study protocol
- drug induced
- deep learning
- artificial intelligence
- red blood cell
- free survival
- cerebral ischemia